Interstitial Lung Disease Secondary to Long-Term Nitrofurantoin Use
Affiliation
Univ Arizona, Coll Med, Dept Internal MedIssue Date
2020-04-02
Metadata
Show full item recordPublisher
INT SCIENTIFIC INFORMATION, INCCitation
Chin, A. J., Rashid, S., Gharibeh, T. R., Kibbe, P. S., & Wynbrandt, J. H. (2020). Interstitial Lung Disease Secondary to Long-Term Nitrofurantoin Use. The American Journal of Case Reports, 21, e920386-1. DOI: 10.12659/AJCR.920386Journal
AMERICAN JOURNAL OF CASE REPORTSRights
© Am J Case Rep, 2020. This work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Objective: Adverse events of drug therapy Background: Interstitial lung disease, also known as diffuse parenchymal lung disease, is a group of diseases that affects the interstitium of the lungs and can lead to progressive fibrosis of the lungs. The potential causes of interstitial lung disease are broad and includes infection, malignancy, autoimmune/connective tissues diseases, inhaled substances, and certain medications. One of the medications that can cause interstitial lung disease is nitrofurantoin. Case Report: A 88-year-old man with recurrent urinary tract infections was treated with long-term nitrofurantoin prophylactic therapy. He took 100 mg of nitrofurantoin on a daily basis for over 10 years as prophylactic therapy for recurrent urinary tract infections, and subsequently developed chronic respiratory failure requiring supplemental oxygen. Chest radiography and high-resolution computed tomography imaging were performed and revealed pulmonary fibrosis consistent with interstitial lung disease. Conclusions: Although nitrofurantoin is one of the most commonly used antibiotics in the treatment of urinary tract infections and is often considered a relatively safe medication, long-term use can lead to the development of interstitial lung disease.Note
Open access journalISSN
1941-5923EISSN
1941-5923PubMed ID
32238797Version
Final published versionae974a485f413a2113503eed53cd6c53
10.12659/AJCR.920386
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © Am J Case Rep, 2020. This work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
Related articles
- Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment.
- Authors: Mikkelsen LF, Rubak S
- Issue date: 2020 Nov 26
- Chronic eosinophilic pneumonia secondary to long-term use of nitrofurantoin: high-resolution computed tomography findings.
- Authors: Martins RR, Marchiori E, Viana SL, Grillo Júnior LS, Capelozzi VL, Valença LM
- Issue date: 2008 Mar
- Nitrofurantoin-Induced Granulomatous Interstitial Pneumonia.
- Authors: Sakata KK, Larsen BT, Boland JM, Palen B, Muhm JR Sr, Helmers RA, Tazelaar HD
- Issue date: 2014 Jun
- Nitrofurantoin-induced interstitial lung disease.
- Authors: Lin DC, Bhally H
- Issue date: 2007 Oct 12
- Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.
- Authors: Sheehan RE, Wells AU, Milne DG, Hansell DM
- Issue date: 2000 Mar-Apr